Clinical trial · Observational
Evaluation of New Biomarkers of Thrombosis in Myeloproliferative Neoplasms
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Thrombosis is the main cause of morbidity and mortality in patients with myeloproliferative neoplasms (MPN). However, the pathogenesis of thrombosis in MPN is still largely elusive. Neutrophils can release their decondensed chromatin as a network of extracellular fibers named NET for "neutrophils extracellular trap". NETs are known to be procoagulant. Our main objective is to quantify NETs biomarkers expression in MPN patients and define if they could be used as prognostic factors in the outcome of thrombosis in these patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myeloproliferative Neoplasm | Myeloproliferative Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 2 additional tubes of blood | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with myeloproliferative neoplasms (MPN)
- description
- Patients diagnosed with Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
- interventionNames
- Biological: 2 additional tubes of blood
Primary outcomes (1)
- measure
- Correlation between NET biomarkers and the risk of thrombosis
- timeFrame
- 1 day
- description
- Correlation between NET biomarkers measurated in plasma samples and the risk of thrombosis evaluated by the prognostic score IPSET thrombosis
Secondary outcomes (3)
- measure
- Correlation between MPO-DNA levels (measured by absorbance at 405 nm) and a history of thrombosis
- timeFrame
- 1 day
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adults (age ≥18 years), * Patients diagnosed with Polycythemia vera (PV) or essential thrombocythemia (ET) according to WHO 2008 criteria, * Affiliated to the national social security system, * Signed informed consent form will be required for each included subject after having read the information note, * Patient agreeing to be included in the FIMBANK register and having signed the corresponding consent Exclusion Criteria: * Adults (age \>18 years), male or female, * Patients treated with heparin or undergoing cytoreductive treatment, * Pregnant or lactating woman, * Person under guardianship, tutorship or other legal protection scheme or incapable of giving consent
References
Publications (0)
Data not yet available